Compare SPAI & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPAI | SCLX |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.0M | 90.0M |
| IPO Year | 2024 | N/A |
| Metric | SPAI | SCLX |
|---|---|---|
| Price | $4.03 | $8.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 199.9K | 69.3K |
| Earning Date | 03-30-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,266,756.00 | ★ $40,360,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $629.15 | $749.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.47 | $3.60 |
| 52 Week High | $9.16 | $34.27 |
| Indicator | SPAI | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 38.65 | 36.63 |
| Support Level | $3.90 | $8.12 |
| Resistance Level | $4.65 | $9.50 |
| Average True Range (ATR) | 0.50 | 0.87 |
| MACD | -0.15 | 0.16 |
| Stochastic Oscillator | 8.65 | 30.31 |
Safe Pro Group Inc operates to acquire security and protection products. Its emphasis is on the development of a cloud-based ecosystem for analyzing drone imagery and data utilizing proprietary artificial intelligence (AI), machine learning, deep learning, and applied computer vision software for hyper-scalable processing, analysis, and reporting. The company operated in three reportable business segments which consisted of: the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. Key revenue is generated from Airborne Response.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.